Log In
BCIQ
Print this Print this
 

vepoloxamer (MST-188) (formerly ANX-188)

Also known as: purified poloxamer 188

  Manage Alerts
Collapse Summary General Information
Company Mast Therapeutics Inc.
DescriptionAntithrombotic poloxamer that binds to hydrophobic surfaces on damaged cells
Molecular Target
Mechanism of Action 
Therapeutic ModalityMacromolecule

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$37.8M

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

04/11/2011

$37.8M

0

Undisclosed

Get a free BioCentury trial today